ReviewDiscover oncology2025
The role of non-coding RNAs in the regulation of cell death pathways in melanoma.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Review
- Innovative immunotherapeutic strategies for thyroid cancer: challenges and opportunities.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Uncovering the Intricate and Heterogeneous Cellular Microenvironment of Cutaneous Melanoma.Medicina (Kaunas, Lithuania) · 2026Review
- Comparative Genomics Reveals Host-Specific Adaptation ofJournal of fungi (Basel, Switzerland) · 2026Article
- Harnessing the potential of gene editing technology for CAR-T cell therapy of solid tumors.Inflammation and regeneration · 2025Review
- Non-coding RNAs-mediated regulation of the MAPK pathway in gastric cancer: translational perspectives.Discover oncology · 2025Review
- Development and validation of nomogram prediction model for diabetic hearing impairment based on the levels of lncRNA MALAT1, miR-199b and AGEs in peripheral blood.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, due to increased exposure to ultraviolet rays, the incidence of melanoma has increased significantly. Despite the progress in early diagnosis and treatment methods, managing metastatic melanoma remains challenging. Resistance to programmed cell death (PCD) is a hallmark of various cancers, including melanoma. This resistance can affect cell growth, survival, metastasis, and resistance to therapies. In recent years, non-coding RNAs (ncRNAs) have been acknowledged as master regulators of various biological processes, including PCD. This regulatory network acts as a double-edged sword in melanoma progression, either promoting tumor survival by preventing PCD or acting as an anti-tumor agent by inducing it. Such diverse functions make ncRNAs invaluable as diagnostic and prognostic biomarkers and potential therapeutic targets. This review explores the multifaceted roles of ncRNAs in regulating different forms of PCD, comprising apoptosis, autophagy, necroptosis, pyroptosis, ferroptosis, cuproptosis, and anoikis, highlighting their potential applications in melanoma research and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.